Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 with or without Adebrelimab in Advanced Biliary Tract Tumors
NCT06620848Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in biliary tract cancer (BTC), sponsored by Zhongshan Hospital, Fudan University. Started Nov 2024; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06620848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620848.